User talk:Deyanyosifov

WP:COI
Please read and follow. Doc James (talk · contribs · email) 17:05, 17 February 2019 (UTC)


 * But to clarify. Citing oneself is frowned up here. Doc James  (talk · contribs · email) 17:06, 17 February 2019 (UTC)


 * I see that the article on CLL already contains quite a big number of citations of primary sources. Why are they allowed in some cases and not in others? Why do you discriminate against me and the citations that I have added (all of them from reputable medical journals)?Deyanyosifov (talk) 17:21, 17 February 2019 (UTC)
 * Just because we have not yet replaced all the other primary sources yet, does not mean you can add your own primary sources. Doc James  (talk · contribs · email) 18:16, 17 February 2019 (UTC)
 * Will you be at least as good as to revert the state of the article to the condition it was in before I updated it? It is really stupid that now ibrutinib (the most widely used targeted drug in CLL, to underline again) is not in the bullet-point list of targeted treatments at all. Irrespective of your rules on who and how should edit and update Wikipedia, it would be good if its contents reflect current state of knowledge and practice to at least a certain extent.Deyanyosifov (talk) 18:25, 17 February 2019 (UTC)
 * Thank you. But to clarify: idelalisib and venetoclax are approved as first-line treatments only in cases with del(17p) and/or TP53 mutation and only if ibrutinib is contraindicated. You can check official approvals by the FDA and the EMA if you don't trust me. Your wording is not quite precise as "A number of medications in this group are first line treatments including venetoclax, ibrutinib, and idelalisib" leaves the impression that they are used only as first-line treatments. In reality, they are also used in refractory CLL, especially venetoclax which is one of the most important drugs for refractory CLL after BTK pathway inhibitors have failed. Then you say "Others include alemtuzumab,[32] rituximab, ofatumumab, obinutuzumab,[32][42] and duvelisib" which by the opposition with the previous sentence suggests that these are not first-line treatments. But the anti-CD20 Abs (rituximab, ofatumumab and obinutuzumab) are also used in first-line treatment. Please be more precise in your writing and don't lead readers to false conclusions.Deyanyosifov (talk) 19:11, 17 February 2019 (UTC)